A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
ECOG-ACRIN EA3191
Description
Protocol#: EA3191
Study Information
Age Group: Adults
Participating Sites: Sanford Bemidji Region; Sanford Bismarck Region; Sanford Fargo Region; Sanford Sioux Falls Region
Scope:
Phase: II
Participating Sites: Sanford Bemidji Region; Sanford Bismarck Region; Sanford Fargo Region; Sanford Sioux Falls Region
Scope:
Phase: II
Principal Investigator(s)
Daniel Almquist
, MD
Department
Management Group:
Head & Neck - Oncology; NCORP
NCT:
NCT04671667
Contact Us
For more information on clinical trials at Sanford Health, call one of our regional clinical research offices:
Sanford Bemidji Region: (218) 333-4869
Sanford Bismarck Region: (701) 323-5760
Sanford Fargo Region: (701) 234-2383
Sanford Sioux Falls Region: (605) 328-1368